全文获取类型
收费全文 | 499346篇 |
免费 | 32786篇 |
国内免费 | 1131篇 |
专业分类
耳鼻咽喉 | 6440篇 |
儿科学 | 15592篇 |
妇产科学 | 14292篇 |
基础医学 | 71336篇 |
口腔科学 | 11889篇 |
临床医学 | 43651篇 |
内科学 | 99021篇 |
皮肤病学 | 9024篇 |
神经病学 | 40783篇 |
特种医学 | 18319篇 |
外国民族医学 | 56篇 |
外科学 | 78636篇 |
综合类 | 11027篇 |
现状与发展 | 3篇 |
一般理论 | 449篇 |
预防医学 | 38567篇 |
眼科学 | 11179篇 |
药学 | 34895篇 |
1篇 | |
中国医学 | 1136篇 |
肿瘤学 | 26967篇 |
出版年
2021年 | 5531篇 |
2020年 | 3403篇 |
2019年 | 5524篇 |
2018年 | 7453篇 |
2017年 | 5767篇 |
2016年 | 6355篇 |
2015年 | 7389篇 |
2014年 | 10459篇 |
2013年 | 15766篇 |
2012年 | 21739篇 |
2011年 | 23376篇 |
2010年 | 13940篇 |
2009年 | 12632篇 |
2008年 | 21896篇 |
2007年 | 23540篇 |
2006年 | 22895篇 |
2005年 | 23028篇 |
2004年 | 22141篇 |
2003年 | 20773篇 |
2002年 | 19922篇 |
2001年 | 15148篇 |
2000年 | 15070篇 |
1999年 | 13415篇 |
1998年 | 5772篇 |
1997年 | 5167篇 |
1996年 | 4787篇 |
1995年 | 4435篇 |
1994年 | 4058篇 |
1993年 | 3820篇 |
1992年 | 9492篇 |
1991年 | 9568篇 |
1990年 | 9291篇 |
1989年 | 9008篇 |
1988年 | 8300篇 |
1987年 | 8072篇 |
1986年 | 7696篇 |
1985年 | 7568篇 |
1984年 | 6204篇 |
1983年 | 5546篇 |
1982年 | 4228篇 |
1981年 | 3652篇 |
1980年 | 3526篇 |
1979年 | 5221篇 |
1978年 | 4156篇 |
1977年 | 3644篇 |
1976年 | 3313篇 |
1975年 | 3506篇 |
1974年 | 4006篇 |
1973年 | 3942篇 |
1972年 | 3540篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Rebecca L. King Albert C. Yan Debora R. Sekiguchi John K. Choi 《Journal of cutaneous pathology》2015,42(12):1012-1017
Reactive lymphoid infiltrates of the skin composed predominantly of gamma‐delta (γδ) T cells are not well described in the literature. Herein we report a case of an otherwise healthy 4‐year‐old male who presented with a waxing and waning papular rash characterized by small, discrete crusted papules spread across his trunk, face and extremities. Clinical evaluation revealed no evidence of systemic disease. Microscopic examination revealed a dermal, perivascular infiltrate of highly atypical lymphocytes with a γδ T cell phenotype, worrisome for primary cutaneous γδ T cell lymphoma. The clinical course, however, was that of a reactive condition and prompted consideration of a diagnosis of pityriasis lichenoides et varioliformis acuta (PLEVA) and lymphomatoid papulosis (LyP). In many ways, this case defies current classification schemes and seems to expand the spectrum of reactive γδ T cell infiltrates of the skin. 相似文献
33.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
34.
35.
36.
37.
38.
39.
40.